Antonio J. Carcas

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia, Antonio J. Carcas, Mayte Pérez‐Olmeda et al. · The Lancet · 2021 · 384 citations · Full text

A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe

Alberto M. Borobia, Antonio J. Carcas, Francisco Arnalich et al. · Journal of Clinical Medicine · 2020 · 289 citations · Full text

Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression

José Ramón Arribas, Federico Pulido, Rafaël Delgado et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2005 · 149 citations

Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

Belén Gutiérrez‐Gutiérrez, María Dolores del Toro, Alberto M. Borobia et al. · The Lancet Infectious Diseases · 2021 · 98 citations · Full text

Prognostic Evaluation, Disease Progression, Multicentre Cohort Study +11

Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score

Juan Berenguer, Alberto M Borobia, Pablo Ryan et al. · Thorax · 2021 · 92 citations · Full text

External Validation, Prognosis, Covid-19 Epidemiology +22